Johnson & Johnson Reports Tremfya Pooled Analysis from GALAXI-2, 3 and QUASAR Trials
Shots:
- J&J reported analysis from pooled data of P-III (GALAXI 2 & 3 and QUASAR) investigating Tremfya in adults with moderately to severely active CD and UC respectively
- In biologic-naïve and biologic-refractory patients P-III GALAXI 2 & 3 showed greater rates of endoscopic remission at week 48 in 44% & 28.1% (100mg, Q8W, SC), 46.1% & 28.6% (200mg, Q4W, SC) of patients treated with Tremfya vs 29.8% & 20.5% treated with Ustekinumab in CD patients
- In biologic-naïve and biologic-refractory patients P-III QUASAR showed greater rates of endoscopic remission at week 44 in 38.1% & 31.2% (100mg, Q8W, SC), 41.7% & 23.9% (200mg, Q4W, SC) of patients treated with Tremfya vs 20.4% & 8% treated with PBO in UC patients
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson Reports the US FDA’s Approval of Tremfya to Treat Ulcerative Colitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
